See more : Kyobo Securities Co ., Ltd (030610.KS) Income Statement Analysis – Financial Results
Complete financial analysis of ATI Inc. (ATI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ATI Inc., a leading company in the Manufacturing – Metal Fabrication industry within the Industrials sector.
You may be interested
- Gold Port Corporation (GPO.CN) Income Statement Analysis – Financial Results
- Guangxi Yuegui Guangye Holdings Co., Ltd. (000833.SZ) Income Statement Analysis – Financial Results
- Biophytis S.A. (ALBPS.PA) Income Statement Analysis – Financial Results
- Clean Earth Acquisitions Corp. (CLINR) Income Statement Analysis – Financial Results
- PT Kimia Farma (Persero) Tbk (KAEF.JK) Income Statement Analysis – Financial Results
ATI Inc. (ATI)
About ATI Inc.
ATI Inc. manufactures and sells specialty materials and components worldwide. The company operates in two segments: High Performance Materials & Components (HPMC) and Advanced Alloys & Solutions (AA&S). The HPMC segment produces various materials, including titanium and titanium-based alloys, nickel- and cobalt-based alloys and superalloys, advanced powder alloys and other specialty materials, in long product forms, such as ingot, billet, bar, rod, wire, shapes and rectangles, and seamless tubes, as well as precision forgings, components, and machined parts. The segment serves aerospace and defense, medical, and energy markets. The AA&S segment produces zirconium and related alloys, including hafnium and niobium, nickel-based alloys, titanium and titanium-based alloys, and specialty alloys in a variety of forms, such as plate, sheet, and precision rolled strip products. It also provides hot-rolling conversion services, including carbon steel products, and titanium products. This segment offers its solutions to the energy, aerospace and defense, automotive, and electronics markets. The company was formerly known as Allegheny Technologies Incorporated. ATI Inc. was founded in 1960 and is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.17B | 3.84B | 2.80B | 2.98B | 4.12B | 4.05B | 3.53B | 3.13B | 3.72B | 4.22B | 4.04B | 5.03B | 5.18B | 4.05B | 3.05B | 5.31B | 5.45B | 4.94B | 3.54B | 2.73B | 1.94B | 1.91B | 2.13B | 2.46B | 2.30B | 3.92B | 3.75B | 3.82B |
| Cost of Revenue | 3.37B | 3.12B | 2.47B | 2.69B | 3.48B | 3.42B | 3.08B | 2.97B | 3.63B | 3.84B | 3.79B | 4.34B | 4.37B | 3.56B | 2.65B | 4.16B | 4.00B | 3.74B | 2.89B | 2.49B | 1.87B | 1.74B | 1.86B | 2.00B | 1.78B | 2.95B | 2.83B | 2.90B |
| Gross Profit | 802.60M | 714.20M | 333.20M | 292.80M | 637.80M | 630.30M | 449.00M | 162.50M | 85.70M | 378.60M | 252.60M | 693.20M | 813.20M | 490.30M | 408.40M | 1.15B | 1.45B | 1.20B | 650.20M | 244.90M | 63.80M | 163.30M | 265.70M | 461.90M | 513.50M | 973.20M | 916.30M | 913.90M |
| Gross Profit Ratio | 19.23% | 18.62% | 11.90% | 9.82% | 15.47% | 15.58% | 12.74% | 5.18% | 2.30% | 8.96% | 6.25% | 13.78% | 15.69% | 12.11% | 13.37% | 21.69% | 26.58% | 24.21% | 18.37% | 8.96% | 3.29% | 8.56% | 12.49% | 18.77% | 22.36% | 24.81% | 24.47% | 23.95% |
| Research & Development | 0.00 | 16.30M | 16.50M | 14.10M | 17.80M | 22.70M | 14.70M | 16.90M | 15.70M | 20.10M | 18.80M | 23.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 62.30M | 62.40M | 55.90M | 40.90M | 65.30M | 57.30M | 50.50M | 43.40M | 44.70M | 49.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 265.80M | 235.10M | 171.00M | 160.10M | 201.90M | 210.90M | 203.80M | 204.30M | 194.10M | 222.90M | 276.40M | 377.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 328.10M | 297.50M | 226.90M | 201.00M | 267.20M | 268.20M | 254.30M | 247.70M | 238.80M | 272.50M | 276.40M | 377.80M | 382.10M | 304.90M | 315.70M | 282.70M | 296.70M | 295.30M | 275.80M | 233.30M | 248.80M | 188.30M | 198.80M | 203.70M | 229.10M | 503.60M | 484.10M | 515.50M |
| Other Expenses | 0.00 | -37.90M | 55.40M | -63.30M | -3.90M | -13.40M | 4.00M | 2.40M | 1.60M | 4.10M | 1.70M | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 328.10M | 297.50M | 226.90M | 201.00M | 267.20M | 268.20M | 254.30M | 247.70M | 238.80M | 272.50M | 276.40M | 377.80M | 382.10M | 304.90M | 315.70M | 282.70M | 296.70M | 295.30M | 275.80M | 233.30M | 248.80M | 188.30M | 198.80M | 203.70M | 324.40M | 503.60M | 484.10M | 515.50M |
| Cost & Expenses | 3.71B | 3.42B | 2.69B | 2.89B | 3.75B | 3.68B | 3.33B | 3.22B | 3.87B | 4.12B | 4.07B | 4.72B | 4.75B | 3.86B | 2.96B | 4.44B | 4.30B | 4.04B | 3.17B | 2.72B | 2.12B | 1.93B | 2.06B | 2.20B | 2.11B | 3.45B | 3.31B | 3.42B |
| Interest Income | 13.00M | 4.70M | 700.00K | 1.70M | 5.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 105.80M | 87.40M | 96.90M | 94.40M | 99.00M | 101.00M | 133.80M | 124.00M | 110.20M | 108.70M | 65.20M | 71.60M | 92.30M | 62.70M | 19.30M | 3.50M | 4.80M | 0.00 | 350.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 146.10M | 152.70M | 153.70M | 151.30M | 160.60M | 166.40M | 170.80M | 180.30M | 189.90M | 176.80M | 189.90M | 194.00M | 174.40M | 141.50M | 132.60M | 118.80M | 102.90M | 84.20M | 77.30M | 76.10M | 74.60M | 90.00M | 98.60M | 99.70M | 95.30M | 109.00M | 98.50M | 105.30M |
| EBITDA | 547.10M | 599.30M | 260.80M | -1.30B | 506.70M | 515.90M | 219.20M | -428.30M | -166.70M | 287.00M | 96.80M | 497.90M | 588.80M | 331.00M | 218.90M | 999.80M | 1.29B | 981.60M | 480.40M | 44.00M | -110.40M | 65.00M | 239.50M | 372.90M | 279.00M | 637.70M | 468.10M | 482.70M |
| EBITDA Ratio | 13.11% | 13.60% | 10.92% | 5.76% | 12.56% | 12.48% | 10.20% | 2.79% | 1.03% | 6.80% | 4.15% | 10.13% | 11.68% | 8.08% | 7.38% | 18.71% | 22.91% | 19.87% | 13.57% | 1.61% | -2.21% | 5.74% | 11.25% | 15.16% | 12.15% | 16.25% | 12.50% | 12.65% |
| Operating Income | 466.40M | 287.30M | 161.70M | 28.50M | 366.10M | 362.10M | 80.30M | -612.40M | -369.40M | 106.10M | -91.30M | 315.40M | 431.10M | 185.40M | 92.70M | 869.20M | 1.15B | 897.40M | 403.10M | -32.10M | -117.50M | 19.50M | 140.90M | 273.20M | 183.70M | 528.70M | 369.60M | 377.40M |
| Operating Income Ratio | 11.17% | 7.49% | 5.78% | 0.96% | 8.88% | 8.95% | 2.28% | -19.54% | -9.93% | 2.51% | -2.26% | 6.27% | 8.32% | 4.58% | 3.03% | 16.37% | 21.03% | 18.17% | 11.39% | -1.17% | -6.06% | 1.02% | 6.62% | 11.10% | 8.00% | 13.48% | 9.87% | 9.89% |
| Total Other Income/Expenses | -171.20M | 38.50M | -107.00M | -179.20M | -124.70M | -114.40M | -166.80M | -121.60M | -108.60M | -104.60M | -63.60M | -71.60M | -91.70M | -59.70M | -27.80M | -1.50M | -5.40M | -31.30M | -67.30M | 51.90M | -2.62B | -78.80M | -103.30M | -49.40M | -14.90M | -137.50M | 56.00M | 42.50M |
| Income Before Tax | 295.20M | 162.00M | 10.60M | -1.48B | 241.60M | 247.70M | -86.50M | -734.00M | -478.00M | 1.50M | -154.80M | 244.00M | 339.40M | 125.70M | 64.90M | 860.10M | 1.15B | 869.20M | 307.10M | 19.80M | -2.80B | -103.80M | -36.40M | 208.80M | 174.20M | 391.20M | 475.20M | 384.70M |
| Income Before Tax Ratio | 7.07% | 4.22% | 0.38% | -49.69% | 5.86% | 6.12% | -2.45% | -23.42% | -12.85% | 0.04% | -3.83% | 4.85% | 6.55% | 3.11% | 2.12% | 16.20% | 21.04% | 17.60% | 8.68% | 0.72% | -144.63% | -5.44% | -1.71% | 8.49% | 7.59% | 9.97% | 12.69% | 10.08% |
| Income Tax Expense | -128.20M | 15.50M | 26.80M | 77.70M | -28.50M | 11.00M | -6.80M | -106.90M | -112.10M | -8.70M | -63.60M | 76.20M | 116.30M | 47.00M | 26.90M | 294.20M | 400.20M | 297.30M | -54.70M | -8.20M | 33.10M | -38.00M | -11.20M | 76.30M | 63.20M | 150.00M | 177.60M | 158.20M |
| Net Income | 410.80M | 130.90M | -16.20M | -1.56B | 257.60M | 222.40M | -91.90M | -640.90M | -377.90M | -2.60M | 154.00M | 158.40M | 214.30M | 70.70M | 31.70M | 565.90M | 747.10M | 571.90M | 359.80M | 19.80M | -314.60M | -65.80M | -25.20M | 132.50M | 300.20M | 241.20M | 297.60M | 213.00M |
| Net Income Ratio | 9.84% | 3.41% | -0.58% | -52.30% | 6.25% | 5.50% | -2.61% | -20.45% | -10.16% | -0.06% | 3.81% | 3.15% | 4.13% | 1.75% | 1.04% | 10.66% | 13.70% | 11.58% | 10.16% | 0.72% | -16.24% | -3.45% | -1.18% | 5.39% | 13.07% | 6.15% | 7.95% | 5.58% |
| EPS | 3.29 | 1.03 | -0.13 | -12.33 | 2.05 | 1.52 | -0.83 | -5.97 | -3.52 | -0.02 | 1.44 | 1.49 | 2.09 | 0.73 | 0.33 | 5.71 | 7.35 | 5.76 | 3.77 | 0.23 | -3.89 | -0.82 | -0.31 | 1.60 | 3.15 | 4.90 | 3.73 | 2.65 |
| EPS Diluted | 2.81 | 0.87 | -0.13 | -12.33 | 1.85 | 1.52 | -0.83 | -5.97 | -3.52 | -0.02 | 1.44 | 1.43 | 1.97 | 0.72 | 0.32 | 5.67 | 7.26 | 5.61 | 3.59 | 0.22 | -3.89 | -0.82 | -0.31 | 1.60 | 3.13 | 4.86 | 3.73 | 2.65 |
| Weighted Avg Shares Out | 128.10M | 127.50M | 127.10M | 126.50M | 125.80M | 145.90M | 110.10M | 107.30M | 107.21M | 107.10M | 106.24M | 106.10M | 102.50M | 97.50M | 97.20M | 99.10M | 101.69M | 99.67M | 96.23M | 86.63M | 80.87M | 80.24M | 81.29M | 82.81M | 95.30M | 96.85M | 87.47M | 88.05M |
| Weighted Avg Shares Out (Dil) | 150.00M | 151.20M | 127.10M | 126.50M | 146.50M | 145.90M | 110.10M | 107.30M | 107.30M | 107.10M | 106.80M | 116.60M | 113.90M | 98.70M | 98.10M | 99.80M | 102.96M | 102.34M | 100.84M | 90.49M | 80.87M | 80.24M | 81.29M | 82.81M | 95.91M | 96.85M | 87.47M | 88.05M |
New Strong Sell Stocks for December 4th
ATI, ARLP and AGL have been added to the Zacks Rank #5 (Strong Sell) List on December 4, 2024.
ATI Physical Therapy Receives Delisting Notice From the New York Stock Exchange
BOLINGBROOK, Ill. , Dec. 3, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. (NYSE: ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, today announced that it received notification from the New York Stock...
New Strong Sell Stocks for December 2nd
ATI, ATS and AGL have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2024.
New Strong Sell Stocks for November 22nd
ATI, AKBA and ALTG have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2024.
New Strong Sell Stocks for November 18th
ATI, BALY and KOF have been added to the Zacks Rank #5 (Strong Sell) List on November 18, 2024.
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year Alignment with U.S. Food and Drug Administration on development requirements for...
For 5th Consecutive Year, ATI Physical Therapy Achieves 'Exceptional' Rating In Patient Quality from the Center For Medicare and Medicaid Services (MIPS)
The Achievement Continues the Company's Streak in Earning the Rating Annually Since the Program Debuted in 2019 BOLINGBROOK, Ill. , Nov. 13, 2024 /PRNewswire/ -- ATI Physical Therapy ("ATI" or the "Company") today has again earned the "Exceptional" rating from...
ATI announces sale of precision rolled strip operations to Ulbrich
Sharpens focus on strategic aerospace and defense markets, streamlines operations DALLAS , Nov. 6, 2024 /PRNewswire/ -- ATI Inc. (NYSE: ATI) announced it completed the sale of its precision rolled strip operations in New Bedford, Massachusetts and Remscheid, Germany to...
ATI Physical Therapy Reports Third Quarter 2024 Results
BOLINGBROOK, Ill. , Nov. 4, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. (NYSE: ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, today reported financial results for the third quarter ended September 30, 2024.
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the November 6, 2024 shareholders meeting HALIFAX, Nova Scotia, Oct....
Source: https://incomestatements.info
Category: Stock Reports